<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03714607</url>
  </required_header>
  <id_info>
    <org_study_id>310/26-04-2018</org_study_id>
    <nct_id>NCT03714607</nct_id>
  </id_info>
  <brief_title>Laser Therapy in Managing Vaginal Prolapse</brief_title>
  <official_title>Management of Vaginal Prolapse Using Laser Therapy: Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National and Kapodistrian University of Athens</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National and Kapodistrian University of Athens</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Efficacy of laser therapy in postmenopausal women with symptomatic prolapse stage &gt;1.
      Assessment tools will include prolapse stage quantification system (POP-Q) and validated
      condition related questionnaires.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Postmenopausal women with symptomatic cystocele and/or rectocele stage 2 or 3 will be 1:1
      randomly allocated to Er:YAG laser or watchful waiting group. Participants in the Er:YAG
      laser group will receive laser therapies at monthly intervals, while participants in the
      watchful waiting group will receive no treatment. All outcomes in both groups will be
      evaluated at baseline, 4-months and 6-months from baseline.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">November 30, 2018</start_date>
  <completion_date type="Anticipated">January 2020</completion_date>
  <primary_completion_date type="Anticipated">December 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pelvic Organ Prolapse Quantification System (POP-Q)</measure>
    <time_frame>Change from baseline to 4-6 months</time_frame>
    <description>Physical examination</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pelvic Floor Distress Inventory Short Form (PFDI)</measure>
    <time_frame>Change from baseline το 4-6 months</time_frame>
    <description>Total score is calculated by adding the scores of 3 scales (Urogenital Distress Inventory (UDI)-6, Pelvic Organ Prolapse Distress Inventory (POPDI)-6 and Colorectal Anal Distress Inventory (CRADI)-8) with a possible range from 0 to 300. Each scale-item could receive values from 0 to 4 applying to a score ranging from 0 to 100 for each scale. The higher the score the more intense are the symptoms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>International Consultation on Incontinence Modular Questionnaire-Female Lower Urinary Tract Symptoms (ICIQ-FLUTS)</measure>
    <time_frame>Change from baseline to 4-6 months</time_frame>
    <description>It is a 12-items questionnaire evaluating nocturia, urgency, bladder pain, frequency, hesitancy, straining, intermittency, urinary incontinence (UI) (urge, stress and unexplained), frequency of urinary incontinence and nocturnal enuresis. Filling, voiding and incontinence symptoms subscales range from 0 to 15, 0 to 12 and 0 to 20, respectively. Additionally, it evaluates impact of individual symptoms with bothering scales that are not incorporated in the overall scores.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pelvic Floor Impact Questionnaire short Form</measure>
    <time_frame>Change from baseline to 4-6 months</time_frame>
    <description>Includes 3 domains (incontinence impact questionnaire (IIQ), Pelvic Organ Prolapse Impact Questionnaire (POPIQ) and Colorectal-anal Impact Questionnaire (CRAIQ) with overall 21-items (7 items in each domain). The total score of PFIQ-7 ranges from 0 to 300 (each domain may receive scores from 0 to 100). The highest the score the greater is the impact</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pelvic Organ Prolapse/Urinary Incontinence Sexual Function Questionnaire Short form</measure>
    <time_frame>Change from baseline to 4-6 months</time_frame>
    <description>It includes 12 items corresponding to behavioral-emotive, physical and partner related domains. Likert scale ranging from always (0 score) to never (4 score) is encompassed. Scores are obtained for all domains individually. The sum of all scores create a total PISQ score. PISQ total score range from 0-125. Higher values indicate better sexual functioning.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patients Global Impression of Improvement</measure>
    <time_frame>4-6 months</time_frame>
    <description>It is a single-item questionnaire aiming to evaluate patients impression of improvement following therapeutic intervention.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with treatment-related adverse events as assessed by CTCAE v4.0</measure>
    <time_frame>Up to 3 months post-treatment</time_frame>
    <description>Women will be asked to keep a diary reporting any adverse events occuring.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Cystocele</condition>
  <condition>Vaginal Vault Prolapse</condition>
  <condition>Rectocele</condition>
  <condition>Enterocele</condition>
  <arm_group>
    <arm_group_label>Laser</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Erbium Yttrium Aluminum Garnet (Er:YAG) laser therapies</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>No intervention</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Erbium Yttrium Aluminum Garnet (Er:YAG) laser</intervention_name>
    <description>5 Er:YAG laser therapies vaginally administered at monthly intervals</description>
    <arm_group_label>Laser</arm_group_label>
    <other_name>Fotona</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Symptomatic prolapse stage &gt;1 (cystocele, vaginal vault prolapse, enterocele,
             rectocele) according to POP-Q System

          -  Negative Pap-smear

        Exclusion Criteria:

          -  Asymptomatic prolapse

          -  prolapse stage &lt;=1

          -  prolapse of uterus

          -  presence of any type of genital infections (i.e herpes, vaginitis etc)

          -  vaginal bleeding

          -  underlying pathologies that could interfere in patients compliance (i.e psychiatric)
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <gender_description>Female</gender_description>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stavros Athanasiou, Associate Proffesor</last_name>
    <role>Study Director</role>
    <affiliation>National and Kapodistrian University of Athens, Greece</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Urogynecological Unit of Alexandra Hospital</name>
      <address>
        <city>Athens</city>
        <zip>11528</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Greece</country>
  </location_countries>
  <verification_date>September 2019</verification_date>
  <study_first_submitted>October 13, 2018</study_first_submitted>
  <study_first_submitted_qc>October 19, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">October 22, 2018</study_first_posted>
  <last_update_submitted>September 15, 2019</last_update_submitted>
  <last_update_submitted_qc>September 15, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">September 17, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>National and Kapodistrian University of Athens</investigator_affiliation>
    <investigator_full_name>Themos Grigoriadis</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rectocele</mesh_term>
    <mesh_term>Cystocele</mesh_term>
    <mesh_term>Uterine Prolapse</mesh_term>
    <mesh_term>Prolapse</mesh_term>
    <mesh_term>Pelvic Organ Prolapse</mesh_term>
    <mesh_term>Hernia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

